Logo

Alopexx Signs an Exclusive License Agreement with Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia

Share this

Alopexx Signs an Exclusive License Agreement with Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia

Shots:

  • Alopexx to receive up front- development & commercialization milestones along with royalties on sales. Beijing Shenogen Pharma get an exclusive license to develop & commercialize DI-Leu16-IL2 in China and other parts of Asia
  • The therapy is evaluated in P-I study assessing DI-LEU16-IL2 in 18 patients with r/r B-cell CD20+ lymphoma who received 2 or more cycles of therapy had tumor regression or stabilization including 3 complete and 2 partial responses
  • DI-LEU16-IL2 is a novel immune-cytokine targeting CD20- developed by Merck KGaA and licensed to Provenance in 2009. Later in 2011- Provenance rights to develop & commercialize the therapy to Alopexx

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Alopexx


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions